NewLink Genetics Corporation (NLNK) Shares Down 1.3%

NewLink Genetics Corporation (NASDAQ:NLNK) shares fell 1.3% on Tuesday . The stock traded as low as $8.11 and last traded at $8.90. 657,600 shares traded hands during trading, a decline of 50% from the average session volume of 1,305,013 shares. The stock had previously closed at $9.02.

Several research firms have recently weighed in on NLNK. Zacks Investment Research lowered shares of NewLink Genetics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. ValuEngine lowered shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics Corporation in a research note on Thursday, November 2nd. Jefferies Group LLC lowered their price objective on shares of NewLink Genetics Corporation from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Finally, Stifel Nicolaus lifted their target price on shares of NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. NewLink Genetics Corporation has an average rating of “Buy” and an average target price of $23.43.

In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction on Friday, October 6th. The stock was purchased at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 13.70% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Eqis Capital Management Inc. lifted its holdings in shares of NewLink Genetics Corporation by 0.6% during the 2nd quarter. Eqis Capital Management Inc. now owns 32,999 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 183 shares during the period. The Manufacturers Life Insurance Company increased its position in NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares in the last quarter. Advisor Group Inc. increased its position in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares in the last quarter. American International Group Inc. increased its position in NewLink Genetics Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock worth $321,000 after purchasing an additional 880 shares in the last quarter. Finally, Northwest Wealth Management LLC increased its position in NewLink Genetics Corporation by 3.1% during the 2nd quarter. Northwest Wealth Management LLC now owns 58,022 shares of the biotechnology company’s stock worth $426,000 after purchasing an additional 1,740 shares in the last quarter. 45.31% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “NewLink Genetics Corporation (NLNK) Shares Down 1.3%” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/15/newlink-genetics-corporation-nlnk-shares-down-1-3.html.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply